Immutep Ltd ( (AU:IMM) ) has shared an update.
Immutep Limited has announced a significant milestone in its TACTI-004 Phase III trial for advanced non-small cell lung cancer (NSCLC) with the first patient dosed at Calvary Mater Newcastle Hospital in Australia. This global trial, which will enroll approximately 756 patients, evaluates the combination of Immutep’s eftilagimod alfa and MSD’s KEYTRUDA® with chemotherapy, aiming to establish a new standard-of-care therapy. The trial’s success could lead to a clinically meaningful survival benefit and potentially change current treatment practices for NSCLC, addressing the high unmet need for effective therapies in this prevalent cancer type.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to stimulate or suppress the immune response, and is committed to providing innovative treatment options to patients while maximizing shareholder value.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $283.7M
Learn more about IMM stock on TipRanks’ Stock Analysis page.